



Dr. Agarwal's Eye Hospital Limited
 Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006
 Phone No. 91-44-39916669, Website : www.dragarwal.com, E-mail : investor@dragarwal.com, CIN : L85110TN1994PLC027366
 Statement of Unaudited Financial Results for the Quarter and Nine months ended 31st December 2015

S.NO	Particulars	Quarter ended				Year to date figures for the period ended		Year ended 31-Mar-15 Audited
		31-Dec-15 Unaudited	30-Sep-15 Unaudited	31-Dec-14 Unaudited	31-Dec-15 Unaudited	31-Dec-14 Unaudited		
1	(a) Net sales/Income from operations (Refer Note 4 below)	2,830.69	3,648.17	2,846.74	10,057.10	8,760.69	11,743.31	
	(b) Other Operating Income	18.12	24.50	16.23	66.48	53.75	71.89	
	Total Income	2,848.81	3,672.67	2,862.97	10,123.58	8,814.44	11,815.20	
2	Expenditure							
	(a) Purchase of Optical and Pharmaceutical Products	310.40	540.09	419.86	1,339.04	1,291.36	1,662.19	
	(b) (Increase) / Decrease in stock of Optical and Pharmaceutical Products	49.58	(47.03)	(8.37)	(41.40)	(39.20)	(13.96)	
	(c) Consumables	283.73	432.10	355.59	1,185.09	969.20	1,201.02	
	(d) Doctor Consultation Charges	471.44	477.31	388.04	1,487.48	1,135.47	1,541.20	
	(e) Employee Benefit Expenses (Refer Note 3 below)	750.14	642.68	547.51	2,052.79	1,630.15	2,166.37	
	(f) Depreciation and Amortisation Expense	223.80	190.94	100.07	590.49	293.35	615.61	
	(g) Rent	390.82	394.32	357.12	1,142.20	1,070.21	1,444.92	
	(h) Other Expenditure	541.54	545.64	569.32	1,711.38	1,667.59	2,358.33	
	(i) Prior Period Items	-	251.71	1.55	542.43	88.94	95.55	
	Total	3,021.45	3,427.76	2,730.69	10,009.50	8,107.07	11,071.23	
3	Profit / (Loss) from Operations before Other Income, Finance cost & Exceptional Items (1-2)	(172.64)	244.91	132.28	114.08	707.37	743.97	
4	Other Income	5.52	6.52	8.10	15.78	37.76	113.14	
5	Profit / (Loss) from Ordinary activities before Finance Cost & Exceptional Items (3+4)	(167.12)	251.43	140.38	129.86	745.13	857.11	
6	Finance Cost	100.89	93.12	78.55	283.01	237.68	320.85	
7	Profit / (Loss) from Ordinary activities after Finance cost but before Exceptional Items (5-6)	(268.01)	158.31	61.83	(153.15)	507.45	536.26	
8	Exceptional Items	-	-	-	-	-	-	
9	Profit / (Loss) from Ordinary Activities before Tax (7+8)	(268.01)	158.31	61.83	(153.15)	507.45	536.26	
10	Tax Expenses							
	- relating to the current period	(89.77)	158.99	20.00	107.75	130.00	181.74	
	- relating to the prior years	-	(91.63)	-	(187.75)	-	(215.28)	
11	Net Profit / (Loss) from Ordinary Activities after Tax (9-10)	(178.24)	90.95	41.83	(73.15)	377.45	589.80	
12	Extraordinary Items (net of tax expense)	-	-	-	-	-	-	
13	Net Profit / (Loss) for the period (11-12)	(178.24)	90.95	41.83	(73.15)	377.45	589.80	
14	Paid-up equity share capital (Face value Rs.10/- each)	470.00	470.00	470.00	470.00	470.00	470.00	
15	Reserves excluding Revaluation Reserves (as per balance sheet) of previous accounting year	-	-	-	-	-	1,905.99	
	Earnings Per Share (EPS) (of Rs.10 each not annualised)							
	(a) Basic	(3.79)	1.94	0.89	(1.56)	8.03	12.12	
	(b) Diluted	(3.79)	1.94	0.89	(1.56)	8.03	12.12	

Notes :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at the Meeting held on 4 February 2016. The Statutory Auditors of Company have carried out a Limited Review of the above Unaudited Financial Results for the Quarter and Nine months ended 31 December 2015.
- The Company has identified business segment as its primary segment and geographic segment as its secondary segment. Effective, 1 July 2015, the Company has reviewed its business oversight mechanism and has realigned all its operations under single business segment i.e. "Eye Care related Sales and Services", based on the assessment of overall risks and rewards. The amounts appearing in these results relate to this primary segment.
- Employee benefit expenses for the period ended 31 December 2015 includes Rs. 34.5 Lacs towards additional provision for bonus made by the Company pursuant to the recent amendment in the Payment of Bonus Act, 1965.
- Operations during the quarter ended 31 December 2015 were impacted due to heavy rain and floods in Chennai and rest of Tamil Nadu.
- Previous period figures have been regrouped / reclassified, wherever necessary to conform with the current period presentation.



By the Order of the Board

Dr. Amar Agarwal
 Chairman & Managing Director
 DIN NO. 00435684


Place : Chennai
 Date : 04.02.2016

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company") for the Quarter and Nine Months ended 31 December 2015 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting AS – 25 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)


Sriraman Parthasarathy
Partner
(Membership No. 206834)

Chennai, 4 February 2016
PS/RB/2016

